NCT04975971View on ClinicalTrials.gov

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions
Anterior Chamber InflammationOcular PainCorneal EdemaCorneal DefectPenetrating KeratoPlastyNuclear CataractCortical CataractCataract Senile
Interventions
DRUG

Dextenza 0.4Mg Ophthalmic Insert

DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

Trial Locations (1)

90067

Advanced Vision Care, Los Angeles

All Listed Sponsors
lead

Nicole Fram M.D.

OTHER

NCT04975971 - A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery | Biotech Hunter | Biotech Hunter